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Abstract
Background: HIV infection of cells varies greatly between individuals, with multiple steps in the
replication cycle potentially contributing to the variability. Although entry and post-entry variability
of HIV infection levels in cells has been demonstrated, variability in HIV binding has not been
examined. In this study, we examined variability of HIV binding to peripheral blood mononuclear
cells (PBMC) from different donors.
Results: HIV binding to PBMC varied up to 3.9-fold between individuals and was independent of
CD4. Replication of HIV in donor PBMC required CD4 and paralleled virus binding trends of donor
PBMC. To assess the stability of virus binding phenotypes over time, HIV was bound to donors with
low- and high-binding phenotypes. The binding phenotypes were maintained when tested weekly
over a 4-week period for 3 of 4 donors, while one high-binding donor decreased to lower binding
on the 4th week. The low- and high-binding phenotypes were also preserved across different HIV
strains. Experiments performed to determine if there was an association between HIV binding
levels and specific cell subset levels within PBMC showed no correlation, suggesting that HIV binds
to multiple cell subsets.
Conclusion: These results show that differences exist in HIV binding to donor PBMC. Our data
also show that HIV binding to donor PBMC is CD4-independent and can change over time,
suggesting that virus binding variability is due to differences in the expression of changeable cell-
surface host factors. Taken together, this study highlights the impact of cell-surface factors in HIV
binding to, and infection of, PBMC which likely represents an important step in HIV infection in vivo.
Background
Infection of cells by HIV requires a number of host cell
factors [1]. Differences in these factors can contribute to
variability in infection levels between individuals. Previ-
ous studies show that HIV infection levels of cells differ
between individuals, with up to a 1000-fold variability in
replication for HIV laboratory-adapted strains [2,3] and
up to a 40-fold variability for HIV primary isolates [4]. The
level of HIV infectivity in cells has been attributed to mul-
tiple steps in the HIV replication cycle, including entry
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and several post-entry events [5]. These studies show that
differences in host factors between individuals can impact
the efficiency of HIV infection.
During the HIV replication cycle nascent virions acquire
host cell-surface molecules that can retain their biological
function. For example, CD54 (ICAM-1) incorporated in
the virus membrane has been shown to facilitate attach-
ment to cells independently of CD4 [6]. Additional stud-
ies have shown HIV attachment independent of CD4:
macrophages can capture HIV through the mannose
receptor and syndecans [7,8], dendritic cells through syn-
decan-3 and a variety of C-type lectin receptors [9-11],
and HeLa cells through cell-surface heparans [12]. Fur-
thermore, we previously showed that the initial attach-
ment of HIV primary isolates to PBMC is independent of
CD4 and not attributable to host factors previously sug-
gested to be involved in HIV attachment to cells [13-15].
Since previous studies suggested that the initial attach-
ment of HIV to PBMC is attributable to host factors, and
that these factors could potentially differ between donor
cells, we hypothesized that HIV attachment variability
exists between donor cells. Heretofore, it has only been
indirectly shown that variability in HIV entry exists
between donor cells [5], however, no study has directly
examined variability in HIV attachment to donor cells. In
this study, we directly tested HIV attachment to donor
PBMC and show high levels of variability in HIV binding
to donor PBMC that occurs independently of CD4 and
virus strain.
Results
We assessed the possibility of differences in HIV binding
to donor PBMC using the R5 primary isolate HIVTH and
freshly isolated PBMC from 19 different healthy donors.
HIV binding was variable between donors, with up to a
3.9-fold difference in virus binding between the highest
and lowest binding donors (Fig. 1A).
We next hypothesized that the variability in HIV binding
would affect infection of PBMC. Donor PBMC from low,
medium and high binding donors were treated with phy-
tohemagglutinin (PHA) for 2 days, HIV was bound to
PBMC and the cells cultured for up to 7 days. Replication
of virus at day 5 post-infection showed a similar trend to
virus bound to donor PBMC on day 0 (Fig. 1B). A similar
trend was observed on day 7 post-infection (data not
shown), although higher levels of replication were
observed, as anticipated. As a control, virus was bound to
PBMC in the presence or absence of PHA stimulation;
there was no difference in virus binding between groups
(data not shown), showing that PHA does not alter PBMC
binding phenotypes.
While previous studies showed that binding of HIV pri-
mary isolates to PBMC was CD4-independent [10-12], we
next sought to confirm this with PBMC donors that
bound HIV at differing levels. The CD4-blocking antibody
Sim.4 did not significantly affect binding of HIV to PBMC
(Fig. 1C). regardless of whether the PBMC donor bound
relatively high levels of virus (e.g. donor 1) or low levels
of virus (e.g. donor 2). To confirm that the Sim.4 antibody
could block infection, HIV was bound to PBMC at in the
presence of Sim.4, an irrelevant antibody, or without anti-
body, and then incubated at 37°C to allow infection of
PBMC to proceed. HIV infection of PBMC was inhibited
with Sim.4, but not the irrelevant antibody (data not
shown).
We next determined whether HIV binding phenotypes of
PBMC donors were stable over time. HIV attachment to
PBMC from two donors with a high-binding phenotype
and two with a low-binding phenotype were examined for
virus binding levels once a week over 4 weeks. A stable
HIV binding pattern was maintained over 4 weeks for
PBMC from both of the donors with a low-binding phe-
HIV binding to PBMC is variable between donors Figure 1
HIV binding to PBMC is variable between donors. (A) 
Freshly isolated PBMC (3 × 106) were incubated with HIVTH 
(2000 pg of p24) in serum-free RPMI-1640 medium for 45 
minutes on ice. After incubation with HIV, cells were washed 
to remove unbound virus. Cells were pelleted, lysed and HIV 
p24 was measured by ELISA. Shown are values from 19 dif-
ferent healthy PBMC donors. (B) HIVTH was bound to 
freshly isolated or PHA-stimulated donor PBMC. For virus 
binding to freshly isolated PBMC, HIV p24 was measured by 
ELISA as described above. HIV replication of donor PBMC 
was assessed by p24 ELISA after 5 days of culture. (C) HIVTH 
was bound to freshly isolated PBMC either in the presence of 
anti-CD4, isotype control antibody, or in the absence of anti-
body. Cell-bound virus was measured as described above. 
Results are the means ± SD of triplicate determinations.
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notype and for one of the donors with a high-binding
phenotype (Fig. 2). However, one donor with a high-
binding phenotype changed to a low-binder on the fourth
week. This data shows that HIV binding phenotypes are
relatively stable over the period of several weeks, but are
also able to change.
Since HIV infection of PBMC is affected by differences in
virus strain [16], we also determined whether the relative
binding of HIV to high- and low-binding PBMC was
affected by the strain of virus. Four different HIV strains –
HIVGP (X4), HIVNL4-3 (X4), HIVTH (R5), or HIVSF2 (X4) –
were incubated with PBMC from one donor with a high-
binding phenotype and one with a low-binding pheno-
type. The high-binding PBMC bound more virus than the
low-binding PBMC for all virus strains tested (Fig. 3). Spe-
cifically, the high-binder PBMC bound 3.1-, 1.7-, 1.5- and
3.9-fold more virus than the low-binder PBMC for HIVGP,
HIVNL4-3, HIVTH, and HIVSF2, respectively. This shows that
HIV binding differences of high- and low-binding PBMC
donors are preserved across multiple virus strains. Since
the HIV binding variability between PBMC donors is not
HIV strain-dependent, this suggests a role in cell binding
of either host cell-acquired molecules on the HIV mem-
brane, or a highly conserved HIV-encoded envelope pro-
tein site.
PBMC are a heterogeneous population of cells composed
primarily of CD4 T cells, CD8 T cells, monocytes, and B
cells. To determine whether donor binding variability is
caused by higher or lower numbers of specific cell subsets
within PBMC, HIV was bound to PBMC from 10 different
donors, and flow cytometry was used to assess the per-
centage of CD4+ T cells (CD4+), CD8+ T cells (CD8+),
monocytes (CD14+), and B cells (CD20+), respectively
(Fig. 4). No correlation was observed between the level of
virus binding and the percentage of CD4+, CD8+, CD14+,
or CD20+ cells, suggesting that virus binding variability
between PBMC donors is due to differences in HIV attach-
ment factors found on multiple types of cells, as opposed
to differences in levels of a particular cell subset.
Discussion
In this study we found that differences exist in the level of
HIV binding to donor PBMC, that binding phenotypes of
the donors are stable over four weeks, and that binding
phenotypes are consistent across several HIV strains.
Importantly, the variability in virus binding to cells corre-
lated with the levels of HIV infection of cells. Ciuffi et al.
reported that infection of cells from different donors was
highly variable, and that 42% of the infection variance
between cell donors was at the level of HIV entry [5]. The
expression of CCR5 on CD4 T cells correlated with HIV
infection levels of these cells [5], but much of this correla-
tion was due to donors that were heterozygous or
homozygous for the CCR5Δ32 allele. However, when
donors that did not have the mutant allele were excluded
HIV attachment phenotypes of PBMC donors are stable over  time Figure 2
HIV attachment phenotypes of PBMC donors are 
stable over time. Freshly isolated PBMC from two donors 
with high-binding phenotypes and two with low-binding phe-
notypes were incubated with 2000 pg of p24 (HIVTH) in 
serum-free medium 45 minutes on ice and bound virus 
assessed as before. Donors that were not available are indi-
cated by ≠.
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HIV binding phenotypes of PBMC donors are maintained  across multiple virus strains Figure 3
HIV binding phenotypes of PBMC donors are main-
tained across multiple virus strains. Freshly isolated 
PBMC were incubated with 2000 pg of p24 (HIVGP, HIVNL4-3, 
HIVTH, or HIVSF2) in serum-free medium for 45 minutes on 
ice. After incubation with HIV, cells were washed to remove 
unattached virus. Cells and bound virus were lysed and HIV 
p24 was measured by ELISA. Results are the means ± SD of 
triplicate determinations.
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from analysis, there remained a greater-than 10-fold dif-
ference in infection between individuals and about 50%
of this was estimated to be due to virus binding and entry
events, suggesting that cell-surface molecules can have
large effects on virus infection of cells. While previous
studies indicate the initial attachment of HIV to cells
occurs independently of CD4 [10-12] and prior to gp120
interaction with CCR5 [17], we confirm in this study that
the variability of HIV binding to donor PBMC is unaf-
fected by the presence of a blocking antibody to CD4,
indicating that the differences observed in the initial
attachment of HIV to donor PBMC occurs by cell-surface
molecules other than CD4.
Although the mechanism of HIV binding variability to
donor PBMC has not been identified, studies performed
in our laboratory show that the initial attachment of HIV
to PBMC occurs in a Ca2+-dependent manner [13], sug-
gesting a potential role for a C-type lectin or other Ca2+-
dependent molecules in HIV binding to PBMC. Fusion of
HIV mediated by HIV gp120/gp41 to permissive cells
does not occur until 10 minutes after virus is added to
cells at 37°C [18] and does not take place at 20°C, while
binding of HIV can occur at 4°C or higher temperatures
[14]. Therefore, the binding we observe is likely prior to
fusion, and antibody inhibition experiments show it is
independent of CD4. Donor binding variability has
important implications for the HIV replication cycle, since
infection of cells by HIV is greatly impacted by the
amount of bound virus during either direct infection of
cells or during transfer of virus between cells [15].
Donor binding variability does not correlate with a specific cell subset within PBMC Figure 4
Donor binding variability does not correlate with a specific cell subset within PBMC. Donor PBMC were stained 
with anti-CD4-FITC, anti-CD8-FITC, anti-CD14-FITC, or anti-CD20-FITC and the percentage of each subset measured by 
flow cytometry. PBMC from donors were also incubated with 2000 pg of p24 (HIVTH), and cell-bound virus was measured by 
ELISA as before. HIV binding variability is plotted on the y-axis and percentage marker positive cell subsets is plotted on the x-
axis. r2 represents the goodness of fit value. Data represent means ± SD of triplicate determinations.
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Conclusion
By showing that high and low HIV-binding phenotypes
exist, these studies highlight the impact of host-acquired
molecules on the initial steps of HIV infection. This study
therefore provides added insight into understanding the
mechanism of HIV tethering to cells, which could poten-
tially lead to the development of drug strategies that
inhibit entry of the virus into cells.
Methods
Cell culture
PBMC were obtained from healthy donors by Ficoll-
Hypaque (Whittaker M.A. Bioproducts, Walkersville, MD)
gradient centrifugation of freshly obtained heparanized
blood. To activate PBMC, 3 μg/ml phytohemagglutinin
(PHA-L; Sigma/Aldrich, St. Louis, MO) was added to cells
in RPMI 1640 medium supplemented with 10% heat
inactivated fetal bovine serum and 50 μg/ml gentamicin
(complete medium). PBMC were cultured for 2 days,
washed, and further cultured in complete medium con-
taining 20 U/ml interleukin-2 (obtained through the
AIDS Research and Reference Reagent Program [ARRRP],
National Institute of Allergy and Infectious Diseases,
National Institutes of Health, from Maurice Gately, Hoff-
man-La Roche, Inc.). All virus strains tested were pro-
duced in PHA-stimulated PBMC of healthy donors as
previously described [19].
HIV binding
PBMC (3 × 106 PHA-stimulated or unstimulated) were
incubated with 100 μl of virus-culture supernatant,
diluted in serum-free RPMI to contain 2000 pg of p24 for
45 min on ice with periodic agitation. After incubation
with HIV, 3 ml of ice-cold phosphate buffered saline
(PBS) was added to cells. Cells were pelleted by centrifu-
gation and then transferred to a new tube and washed to
prevent measurement of HIV binding to tubes. Pelleted
cells were lysed with 0.5% Triton X-100, and the amount
of virus bound to cells was measured by p24 antigen
ELISA (National Institutes of Health AIDS Vaccine Pro-
gram, Frederick, MD). For experiments with blocking anti-
body, either anti-CD4 (Clone Sim.4, obtained from
American Type Culture Collection, ATCC; IgG1), an iso-
type control antibody (Clone G18-145, ATCC; IgG1), or
no antibody was added to tubes at the beginning of the
virus/PBMC incubation step.
HIV infection
For infection of PBMC, freshly isolated PBMC were cul-
tured in complete medium with 3 μg/ml PHA for 48 h and
then washed prior to HIV binding. Cells were incubated
with HIV and washed as described above. PBMC were
then transferred to 24-well plates (Corning Inc., Corning,
NY) and cultured in medium with 20 U/ml IL-2 in a total
volume of 1 ml. HIV p24 in culture supernatants was
measured by ELISA on days 5 and 7. Cultures were fed on
days 5 and 7 by removal of 500 μl and replacement with
fresh medium containing IL-2.
Flow cytometry
All antibodies (anti-CD4, -CD8, -CD14, -CD20 and iso-
type control) were FITC-conjugated mouse anti-human
IgG (Becton Dickinson, Franklin Lakes, New Jersey). To
assess the expression of cell-surface markers, PBMC were
incubated with the manufacturer's recommended volume
of antibody on ice for 30 min, and then assessed for sur-
face-markers by flow cytometry. For each PBMC donor,
the percentage of surface-marker positive cells was plotted
against the amount of HIV bound to donor PBMC.
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